125 related articles for article (PubMed ID: 20332468)
41. Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
Fiorentini G; Rossi S; Lanzanova G; Biancalani M; Palomba A; Bernardeschi P; Dentico P; De Giorgi U
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):17-20. PubMed ID: 16767900
[TBL] [Abstract][Full Text] [Related]
42. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
Holtkamp N; Okuducu AF; Mucha J; Afanasieva A; Hartmann C; Atallah I; Estevez-Schwarz L; Mawrin C; Friedrich RE; Mautner VF; von Deimling A
Carcinogenesis; 2006 Mar; 27(3):664-71. PubMed ID: 16357008
[TBL] [Abstract][Full Text] [Related]
43. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate.
Mitsuhashi T; Nakayama M; Sakurai S; Fujimura M; Shimizu Y; Ban S; Ogawa F; Hirose T; Ishihara O; Shimizu M
Ann Diagn Pathol; 2007 Feb; 11(1):49-54. PubMed ID: 17240308
[TBL] [Abstract][Full Text] [Related]
44. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
Martins AS; Ordoñez JL; García-Sánchez A; Herrero D; Sevillano V; Osuna D; Mackintosh C; Caballero G; Otero AP; Poremba C; Madoz-Gúrpide J; de Alava E
Cancer Res; 2008 Aug; 68(15):6260-70. PubMed ID: 18676850
[TBL] [Abstract][Full Text] [Related]
45. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
46. Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma.
Altuna X; Lopez JP; Yu MA; Arandazi MJ; Harris JP; Wang-Rodriguez J; An Y; Dobrow R; Doherty JK; Ongkeko WM
Otol Neurotol; 2011 Jan; 32(1):163-70. PubMed ID: 21157293
[TBL] [Abstract][Full Text] [Related]
47. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.
Chugh R; Wathen JK; Maki RG; Benjamin RS; Patel SR; Meyers PA; Priebat DA; Reinke DK; Thomas DG; Keohan ML; Samuels BL; Baker LH
J Clin Oncol; 2009 Jul; 27(19):3148-53. PubMed ID: 19451433
[TBL] [Abstract][Full Text] [Related]
48. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Huh WK; Sill MW; Darcy KM; Elias KM; Hoffman JS; Boggess JF; Alvarez RD; Long HJ; O'Malley DM; Birrer MJ
Gynecol Oncol; 2010 May; 117(2):248-54. PubMed ID: 20189232
[TBL] [Abstract][Full Text] [Related]
50. Imatinib mesylate in thymic epithelial malignancies.
Palmieri G; Marino M; Buonerba C; Federico P; Conti S; Milella M; Petillo L; Evoli A; Lalle M; Ceribelli A; Merola G; Matano E; Sioletic S; De Placido S; Di Lorenzo G; Damiano V
Cancer Chemother Pharmacol; 2012 Feb; 69(2):309-15. PubMed ID: 21710245
[TBL] [Abstract][Full Text] [Related]
51. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
Dy GK; Miller AA; Mandrekar SJ; Aubry MC; Langdon RM; Morton RF; Schild SE; Jett JR; Adjei AA
Ann Oncol; 2005 Nov; 16(11):1811-6. PubMed ID: 16087693
[TBL] [Abstract][Full Text] [Related]
52. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
[TBL] [Abstract][Full Text] [Related]
53. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
54. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma.
Johnson FM; Krug LM; Tran HT; Shoaf S; Prieto VG; Tamboli P; Peeples B; Patel J; Glisson BS
Cancer; 2006 Jan; 106(2):366-74. PubMed ID: 16342249
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of imatinib in advanced chordoma.
Stacchiotti S; Longhi A; Ferraresi V; Grignani G; Comandone A; Stupp R; Bertuzzi A; Tamborini E; Pilotti S; Messina A; Spreafico C; Gronchi A; Amore P; Vinaccia V; Casali PG
J Clin Oncol; 2012 Mar; 30(9):914-20. PubMed ID: 22331945
[TBL] [Abstract][Full Text] [Related]
56. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling.
Posadas EM; Kwitkowski V; Kotz HL; Espina V; Minasian L; Tchabo N; Premkumar A; Hussain MM; Chang R; Steinberg SM; Kohn EC
Cancer; 2007 Jul; 110(2):309-17. PubMed ID: 17559139
[TBL] [Abstract][Full Text] [Related]
57. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
Ströbel P; Hartmann M; Jakob A; Mikesch K; Brink I; Dirnhofer S; Marx A
N Engl J Med; 2004 Jun; 350(25):2625-6. PubMed ID: 15201427
[No Abstract] [Full Text] [Related]
58. Good clinical response to imatinib mesylate in atypical thymic carcinoid With KIT overexpression.
Hamada S; Masago K; Mio T; Hirota S; Mishima M
J Clin Oncol; 2011 Jan; 29(1):e9-10. PubMed ID: 20876428
[No Abstract] [Full Text] [Related]
59. Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity.
Tamborini E; Bonadiman L; Albertini V; Pierotti MA; Pilotti S
J Natl Cancer Inst; 2003 Jul; 95(14):1087-8; author reply 1088-9. PubMed ID: 12865456
[No Abstract] [Full Text] [Related]
60. Oxidative stress and therapeutic opportunities: focus on the Ewing's sarcoma family of tumors.
Smith DG; Magwere T; Burchill SA
Expert Rev Anticancer Ther; 2011 Feb; 11(2):229-49. PubMed ID: 21342042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]